We investigated the relationship of ischemia-modified albumin (IMA) and high-sensitivity C-reactive protein (hsCRP) levels with direct (endocan) and indirect (carotid intima-media thickness [cIMT] and 24 hours urine protein excretion) endothelial dysfunction indicators in type 2 diabetes mellitus (T2DM). Patients with T2DM (n = 88) and 88 healthy individuals were included in the study. The median endocan (475.15 vs 216.37 pg/mL; P < .001, respectively) and hsCRP (10.74 vs 3.11 mg/L; P < .001, respectively) and the mean IMA (0.64 ± 0.12 vs 0.51 ± 0.12 absorbance units; P < .001, respectively) levels were higher in participants with endothelial dysfunction compared to those without endothelial dysfunction in T2DM. The 24-hour urine protein excretion and cIMT levels had a positive correlation with hsCRP ( r = .357; P = .001 and r = .592; P < .001, respectively), IMA ( r = .519; P < .001 and r = .495; P < .001, respectively) and endocan ( r = .347; P = .001 and r = .583; P < .001, respectively) levels in the T2DM group. Stepwise multivariable logistic regression analysis, which included laboratory findings found to be associated with endothelial dysfunction, showed that endocan (odds ratio [OR] = 1.456; P = .004), hsCRP (OR = 1.298; P = .008), and IMA (OR = 2.270, P = .003) were independent risk factors. It was found that none of these markers were superior in terms of diagnostic discrimination for endothelial dysfunction. Endocan, IMA, and hsCRP levels were found to be associated with endothelial dysfunction in patients with T2DM.
BACKGROUND: Acute appendicitis (AA) is one of the major causes of acute abdomen pain. Various laboratory markers have been studied for diagnosis of AA, but none of them have shown superiority to physical examination or imaging. GCP-2/CXCL6 is a chemokine expressed by macrophages and epithelial and mesenchymal cells during inflammation. The present study aims to investigate the diagnostic role of GCP-2/CXCL6 in AA patients. METHODS: In this cross-sectional study, the serum level of GCP-2/CXCL6 was measured in 56 AA patients and 32 healthy control subjects. Also, hs-CRP and white blood cell count (WBC) levels of the patient and control groups were evaluated. RESULTS: GCP-2/CXCL-6, hs-CRP and WBC levels of the AA group were significantly higher than the control group (p<0.05 for all comparisons). Among AA group, GCP-2/CXCL6 levels were higher in complex AA (gangrenous, abscess and perforation) ones when compared to non-complex AA (p<0.05). A strong positive correlation was found between GCP-2/CXCL6 levels and hs-CRP levels (r=0.756, p=0.003) and a moderate positive correlation between GCP-2/CXCL6 levels and WBC count (r=0.468, p=0.003). CONCLUSION: GCP-2/CXCL6 can be a useful marker in AA diagnosis and discrimination of complex cases, especially if combined with other laboratory markers and imaging techniques.
Ö ÖZ ZE ET T A Am ma aç ç: : Bu çalışmada vitiligo ile insülin direnci ve metabolik sendrom (MetS) arasındaki ilişkinin araştırılması amaçlandı. G Ge er re eç ç v ve e Y Yö ön nt te em ml le er r: : Prospektif, gözlemsel vaka-kontrol çalışması olarak planlanmış olan araştırmamıza vitiligo tanısı ile takip edilmekte olan 40 hasta ve hastalar ile yaş ve cinsiyet bakımından benzer 23 sağlıklı kontrol dahil edildi. Açlık kan örneklerinden; glukoz, insülin, C-peptit düzeyleri ve lipid profilleri çalışıldı. İnsülin direnci, HOMA-IR (Homeostatis Model Assessment Insulin Resistance) metodu ile hesaplandı. Ayrıca katılımcıların vücut kitle indeksleri hesaplandı, bel çevresi ve sistolik -diastolik kan basıncı ölçümleri kaydedildi. MetS tanısı, güncellenmiş Ulusal Kolesterol Eğitim Programı Erişkin Tedavi Paneli III kriterlerine göre konuldu. B Bu ul lg gu ul la ar r: : Serum insülin düzeyi vitiligo hastalarında kontrol grubundan yüksek iken (p=0,09), insülin direnci varlığı açısından vitiligo (%27,5) ve kontrol (%21,7) grupları arasında fark yoktu (p=0,61). Vitiligo ile MetS ilişkisi incelendiğinde vitiligo hastalarının %30'unda MetS görülürken, kontrollerin %26,1'inde MetS saptandı (p=0,74). MetS ile cinsiyet, vitiligo tipi, hastalık süresi ve yaygınlığı arasında anlamlı bir ilişki saptanmadı. Trigliserit düzeyi yüksekliği vitiligo hastalarının %35'inde ve kontrol grubunun %13'ünde mevcuttu (p= 0,059). MetS'un diğer parametreleri açısından vitiligo ve kontrol grubu arasında fark saptanmadı. S So on nu uç ç: : Çalışmamızda vitiligo hastalarında dikkate değer bir şekilde serum insülin düzeyi daha yüksek ve trigliserit düzeyi yüksekliği daha sık tespit edilmiş olsa da kontrol grubu ile aradaki farklar anlamlı değildir. Ayrıca, vitiligo hastalarında insülin direnci veya MetS prevalansında anlamlı bir artış saptanmamıştır.A An na ah ht ta ar r K Ke el li im me el le er r: : Vitiligo; insülin direnci; metabolik sendrom; oksidatif stres A AB BS ST TR RA AC CT T O Ob bj je ec ct ti iv ve e: : The aim of this study was to investigate the relationship of vitiligo with insulin resistance and metabolic syndrome (MetS). M Ma at te er ri ia al l a an nd d M Me et th ho od ds s: : Forty vitiligo patients and 23 age-and gender-matched healthy controls were included in this prospective, observational case-control study. Fasting blood glucose, insulin, C-peptide levels and lipid profiles were quantified. Insulin resistance was calculated with the homeostatis model assessment insulin resistance (HOMA-IR) method. Body mass index, waist circumference and systolic-diastolic blood pressure measurements of the participants were recorded. MetS diagnosis was established according to the revised criteria of National Cholesterol Education Program Adult Treatment Panel III. R Re es su ul lt ts s: : Serum insulin level was higher in vitiligo patients than the control group (p=0.09); however there was no difference in terms of insulin resistance between vitiligo (27.5%) and control (21.7%) groups (p=0.61). MetS was detected in 30% of the vitiligo patie...
BACKGROUND: Although Ranson score is the most commonly used prognostic model in the severity of acute pancreatitis (AP), ischemia-modified albumin (IMA) has been reported as a novel biomarker of various ischemia-based diseases in recent years. The aim of the present study is to investigate the correlation between Ranson score and IMA in patients with AP.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.